These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28045204)

  • 1. Increased non-melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective single-centre cohort study.
    Clowry J; Sheridan J; Healy R; Deady S; Keegan D; Byrne K; Cullen G; Mulcahy H; Comber H; Parnell AC; Doherty G; Lally A
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):978-985. PubMed ID: 28045204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.
    Long MD; Martin CF; Pipkin CA; Herfarth HH; Sandler RS; Kappelman MD
    Gastroenterology; 2012 Aug; 143(2):390-399.e1. PubMed ID: 22584081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of non-melanoma skin cancer in New Zealand in inflammatory bowel disease patients treated with thiopurines.
    Bahi M; Walmsley RS; Gray AR; Young D; Hobbs CE; Aluzaite K; Schultz M
    J Gastroenterol Hepatol; 2018 May; 33(5):1047-1052. PubMed ID: 29105142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
    McKenna MR; Stobaugh DJ; Deepak P
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A More Severe Non-melanoma Skin Cancer Phenotype Is Seen in Patients with Inflammatory Bowel Disease on Tumor Necrosis Factor-α Antagonists.
    Townsend CM; Khanna R; Wilson AS
    Dig Dis Sci; 2021 Dec; 66(12):4436-4440. PubMed ID: 33428042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease.
    Long MD; Herfarth HH; Pipkin CA; Porter CQ; Sandler RS; Kappelman MD
    Clin Gastroenterol Hepatol; 2010 Mar; 8(3):268-74. PubMed ID: 20005977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risks of Melanoma and Nonmelanoma Skin Cancers Pre- and Post-Inflammatory Bowel Disease Diagnosis.
    Narous M; Nugent Z; Singh H; Bernstein CN
    Inflamm Bowel Dis; 2023 Jul; 29(7):1047-1056. PubMed ID: 35929649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.
    Scott FI; Mamtani R; Brensinger CM; Haynes K; Chiesa-Fuxench ZC; Zhang J; Chen L; Xie F; Yun H; Osterman MT; Beukelman T; Margolis DJ; Curtis JR; Lewis JD
    JAMA Dermatol; 2016 Feb; 152(2):164-72. PubMed ID: 26510126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
    Peyrin-Biroulet L; Khosrotehrani K; Carrat F; Bouvier AM; Chevaux JB; Simon T; Carbonnel F; Colombel JF; Dupas JL; Godeberge P; Hugot JP; Lémann M; Nahon S; Sabaté JM; Tucat G; Beaugerie L;
    Gastroenterology; 2011 Nov; 141(5):1621-28.e1-5. PubMed ID: 21708105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonmelanoma Skin Cancer Risk in Patients With Inflammatory Bowel Disease Undergoing Thiopurine Therapy: A Systematic Review of the Literature.
    Hagen JW; Pugliano-Mauro MA
    Dermatol Surg; 2018 Apr; 44(4):469-480. PubMed ID: 29315147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
    Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
    Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort.
    Abbas AM; Almukhtar RM; Loftus EV; Lichtenstein GR; Khan N
    Am J Gastroenterol; 2014 Nov; 109(11):1781-93. PubMed ID: 25244964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: A systematic review and meta-analysis.
    Huang SZ; Liu ZC; Liao WX; Wei JX; Huang XW; Yang C; Xia YH; Li L; Ye C; Dai SX
    J Gastroenterol Hepatol; 2019 Mar; 34(3):507-516. PubMed ID: 30393891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer and immunomodulators in inflammatory bowel diseases.
    Biancone L; Onali S; Petruzziello C; Calabrese E; Pallone F
    Inflamm Bowel Dis; 2015 Mar; 21(3):674-98. PubMed ID: 25545375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
    Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III).
    Magro F; Peyrin-Biroulet L; Sokol H; Aldeger X; Costa A; Higgins PD; Joyce JC; Katsanos KH; Lopez A; de Xaxars TM; Toader E; Beaugerie L
    J Crohns Colitis; 2014 Jan; 8(1):31-44. PubMed ID: 23721759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis.
    Singh S; Nagpal SJ; Murad MH; Yadav S; Kane SV; Pardi DS; Talwalkar JA; Loftus EV
    Clin Gastroenterol Hepatol; 2014 Feb; 12(2):210-8. PubMed ID: 23644389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis.
    Ariyaratnam J; Subramanian V
    Am J Gastroenterol; 2014 Feb; 109(2):163-9. PubMed ID: 24419479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Factors and Clinical Outcomes in Patients with IBD with Melanoma.
    Nissen LHC; Pierik M; Derikx LAAP; de Jong E; Kievit W; van den Heuvel TRA; van Rosendael AR; Plasmeijer EI; Dewint P; Verhoeven RHA; Overbeek LIH; Nagtegaal ID; Hoentjen F; van der Meulen-de Jong AE
    Inflamm Bowel Dis; 2017 Nov; 23(11):2018-2026. PubMed ID: 28837522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
    Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
    Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.